Progress toward an Epstein-Barr virus vaccine.

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Epstein-Barr virus (EBV), or Human gammaherpesvirus 4, infects over 90% of the global adult population.
• EBV establishes lifelong latency in B lymphocytes and is linked to various diseases, including infectious mononucleosis, cancers, and chronic inflammatory conditions.
• A recent study identified EBV as the primary trigger for multiple sclerosis (MS).

Purpose of the Study:

• To review the epidemiology of EBV-associated diseases.
• To detail EBV biology, lifecycle, and potential vaccine target antigens.
• To evaluate the immune response to natural infection and assess current vaccine candidates against established benchmarks.

Main Methods:

• Epidemiological data analysis of EBV-associated cancers and inflammatory diseases.
• Review of EBV virology, including its lifecycle and immune evasion strategies.
• Assessment of prophylactic and therapeutic vaccine strategies, including target antigens and immune correlates of protection.

Main Results:

• EBV is the leading cause of multiple sclerosis, necessitating preventative strategies.
• Key viral antigens and immune responses relevant to vaccine development have been identified.
• Existing vaccine candidates are evaluated against defined Target Product Profiles (TPPs).

Conclusions:

• Preventing EBV infection is a critical strategy for eliminating the majority of MS cases worldwide.
• The development of next-generation EBV vaccines is urgently needed and accelerated by recent discoveries.
• Strategic collaboration and clear clinical endpoints are essential for the successful global implementation of an EBV vaccine.